

**Company Registration No. 08553682 (England and Wales)**

**REACTA BIOTECH LIMITED**  
**UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**  
**PAGES FOR FILING WITH REGISTRAR**

# REACTA BIOTECH LIMITED

## CONTENTS

---

	Page
Balance sheet	1 - 2
Statement of changes in equity	3
Notes to the financial statements	4 - 8

---

# REACTA BIOTECH LIMITED

## BALANCE SHEET

AS AT 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
<b>Fixed assets</b>					
Tangible assets	4		122,451		81,268
<b>Current assets</b>					
Stocks		14,330		15,741	
Debtors	5	443,283		286,463	
Cash at bank and in hand		2,185,640		233,880	
		<u>2,643,253</u>		<u>536,084</u>	
<b>Creditors: amounts falling due within one year</b>	6	<u>(1,498,940)</u>		<u>(618,574)</u>	
<b>Net current assets/(liabilities)</b>			1,144,313		(82,490)
<b>Total assets less current liabilities</b>			<u>1,266,764</u>		<u>(1,222)</u>
<b>Creditors: amounts falling due after more than one year</b>	7		<u>(49,800)</u>		<u>(60,965)</u>
<b>Net assets/(liabilities)</b>			<u>1,216,964</u>		<u>(62,187)</u>
<b>Capital and reserves</b>					
Called up share capital	8		1,345		909
Share premium account			6,336,354		3,693,918
Profit and loss reserves			<u>(5,120,735)</u>		<u>(3,757,014)</u>
<b>Total equity</b>			<u>1,216,964</u>		<u>(62,187)</u>

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.

For the financial year ended 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

# **REACTA BIOTECH LIMITED**

## **BALANCE SHEET (CONTINUED)**

***AS AT 31 DECEMBER 2021***

---

The financial statements were approved by the board of directors and authorised for issue on 17 June 2022 and are signed on its behalf by:

A A Woodcock  
**Director**

**Company Registration No. 08553682**

# REACTA BIOTECH LIMITED

## STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Share capital £	Share premium account £	Profit and loss reserves £	Total £
<b>Balance at 1 January 2020</b>		612	2,274,479	(2,855,166)	(580,075)
<b>Year ended 31 December 2020:</b>					
Loss and total comprehensive income for the year		-	-	(901,848)	(901,848)
Issue of share capital	8	297	1,419,439	-	1,419,736
<b>Balance at 31 December 2020</b>		909	3,693,918	(3,757,014)	(62,187)
<b>Year ended 31 December 2021:</b>					
Loss and total comprehensive income for the year		-	-	(1,363,721)	(1,363,721)
Issue of share capital	8	436	2,642,436	-	2,642,872
<b>Balance at 31 December 2021</b>		1,345	6,336,354	(5,120,735)	1,216,964

# REACTA BIOTECH LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

---

### 1 Accounting policies

#### Company information

Reacta Biotech Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 2 Newtech Square, Deeside Industrial Park, Deeside, CH5 2NT.

#### 1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### 1.2 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

#### 1.3 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings Leasehold	20% straight line
Fixtures, fittings & equipment	15% straight line
Plant & machinery	15% straight line
Computer equipment	33% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

#### 1.4 Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

# REACTA BIOTECH LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

---

### 1 Accounting policies

(Continued)

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

#### 1.5 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

#### 1.6 Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.7 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

##### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

##### **Classification of financial liabilities**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

# REACTA BIOTECH LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

---

### 1 Accounting policies

(Continued)

#### **Basic financial liabilities**

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

### 1.8 Taxation

The tax expense represents the sum of the tax currently payable.

#### **Current tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

### 1.9 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

### 1.10 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

### 1.11 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.



# REACTA BIOTECH LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

### 2 Judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 3 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2021 Number	2020 Number
Total	16	12

### 4 Tangible fixed assets

	Land and buildings Leasehold	Fixtures, fittings & equipment	Plant & machinery	Computer equipment	Total
	£	£	£	£	£
<b>Cost</b>					
At 1 January 2021	17,624	1,314	86,736	31,650	137,324
Additions	-	23,936	36,178	11,176	71,290
At 31 December 2021	17,624	25,250	122,914	42,826	208,614
<b>Depreciation and impairment</b>					
At 1 January 2021	8,838	295	32,736	14,187	56,056
Depreciation charged in the year	3,524	1,654	17,016	7,913	30,107
At 31 December 2021	12,362	1,949	49,752	22,100	86,163
<b>Carrying amount</b>					
At 31 December 2021	5,262	23,301	73,162	20,726	122,451
At 31 December 2020	8,786	1,019	54,000	17,463	81,268

# **REACTA BIOTECH LIMITED**

## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 31 DECEMBER 2021**

<b>5 Debtors</b>	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
<b>Amounts falling due within one year:</b>		
Trade debtors	228,431	77,743
Other debtors	214,852	208,720
	<u>443,283</u>	<u>286,463</u>
	<u><u>443,283</u></u>	<u><u>286,463</u></u>
 <b>6 Creditors: amounts falling due within one year</b>	 <b>2021</b>	 <b>2020</b>
	<b>£</b>	<b>£</b>
Trade creditors	1,090,608	291,643
Taxation and social security	80,442	35,922
Other creditors	327,890	291,009
	<u>1,498,940</u>	<u>618,574</u>
	<u><u>1,498,940</u></u>	<u><u>618,574</u></u>
 <b>7 Creditors: amounts falling due after more than one year</b>	 <b>2021</b>	 <b>2020</b>
	<b>£</b>	<b>£</b>
Bank loans and overdrafts	49,800	60,965
	<u>49,800</u>	<u>60,965</u>
	<u><u>49,800</u></u>	<u><u>60,965</u></u>
 <b>8 Called up share capital</b>	 <b>2021</b>	 <b>2020</b>
	<b>£</b>	<b>£</b>
<b>Ordinary share capital</b>		
<b>Issued and fully paid</b>		
1,276,020 ordinary shares of 0.1p each	1,276	845
68,550 ordinary A shares of 0.1p each	69	64
	<u>1,345</u>	<u>909</u>
	<u><u>1,345</u></u>	<u><u>909</u></u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.